Literature DB >> 12352188

Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas.

Hongxiu Ji1, Christina Isacson, Jeffrey D Seidman, Robert J Kurman, Brigitte M Ronnett.   

Abstract

The distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors (atypical proliferative/borderline and carcinoma) can be difficult because of similarities in morphology. We evaluated the immunohistochemical expression of cytokeratins 7 and 20 (CK 7, CK 20), Dpc4 (nuclear transcription factor inactivated in 55% of pancreatic carcinomas), and MUC5AC (a gastric mucin gene) in 57 primary ovarian mucinous tumors (41 atypical proliferative tumors and 16 carcinomas) and 46 metastatic mucinous carcinomas in the ovary. Primary ovarian mucinous tumors were virtually always diffusely positive for CK 7 (98%), Dpc4 (100%), and MUC5AC (98%) and often focally to diffusely positive for CK 20 (68%). Colorectal mucinous carcinomas were diffusely positive for CK 20 (100%) and Dpc4 (89%) and were distinguished from primary ovarian mucinous tumors by their frequent lack of expression of CK 7 and MUC5AC (67% were negative for each marker). Appendiceal carcinomas were diffusely positive for CK 20 (100%) and often negative for CK 7 (71%) but were often positive for MUC5AC (86%) and Dpc4 (100%). When primary ovarian and metastatic colorectal or appendiceal carcinomas shared expression of both CK 7 and CK 20, they could usually be distinguished by the pattern of positivity (diffuse CK 7 and patchy CK 20 in ovarian tumors and patchy CK 7 and diffuse CK 20 in colorectal and appendiceal tumors). Pancreatic carcinomas shared the same pattern of diffuse positivity for CK 7 (100%) and MUC5AC (92%) and focal to diffuse positivity for CK 20 (71%) as primary ovarian mucinous tumors but were negative for Dpc4 in 46%. Loss of Dpc4 expression is useful for distinguishing metastatic pancreatic carcinomas in the ovary from both primary ovarian mucinous tumors and metastatic mucinous carcinomas derived from other sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352188     DOI: 10.1097/00004347-200210000-00009

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  38 in total

1.  Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; Mark F Brady; Subodh M Lele; Helen Michael; Benjamin Greer; Michael A Bookman
Journal:  Cancer       Date:  2010-09-22       Impact factor: 6.860

2.  New tumor-associated antigen SC6 in pancreatic cancer.

Authors:  Min-Pei Liu; Xiao-Zhong Guo; Jian-Hua Xu; Di Wang; Hong-Yu Li; Zhong-Min Cui; Jia-Jun Zhao; Li-Nan Ren
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 3.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

Review 4.  Primary retroperitoneal mucinous cystadenocarcinoma in a male patient.

Authors:  T P Thamboo; R Sim; S-Y Tan; W-M Yap
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

Review 5.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

Review 6.  Appendiceal Mucinous Neoplasms: Diagnosis and Management.

Authors:  Walid L Shaib; Rita Assi; Ali Shamseddine; Olatunji B Alese; Charles Staley; Bahar Memis; Volkan Adsay; Tanios Bekaii-Saab; Bassel F El-Rayes
Journal:  Oncologist       Date:  2017-06-29

7.  Trefoil factor 1 elevates the malignant phenotype of mucinous ovarian cancer cell through Wnt/β-catenin signaling.

Authors:  Shan Zhao; Yumei Ma; Xianghua Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Gastric-type mucinous adenocarcinoma of the uterine cervix with neoadjuvant therapy mimicking clear cell carcinoma.

Authors:  Yifen Zhang; Li Liang; Elizabeth D Euscher; Jinsong Liu; Preetha Ramalingam
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Mucinous adenocarcinoma involving the ovary: comparative evaluation of the classification algorithms using tumor size and laterality.

Authors:  Eun Sun Jung; Jeong Hoon Bae; Ahwon Lee; Yeong Jin Choi; Jong-Sup Park; Kyo-Young Lee
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

10.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

Authors:  Jessica N McAlpine; Kimberly C Wiegand; Russell Vang; Bridgett M Ronnett; Anna Adamiak; Martin Köbel; Steve E Kalloger; Kenneth D Swenerton; David G Huntsman; C Blake Gilks; Dianne M Miller
Journal:  BMC Cancer       Date:  2009-12-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.